Arcalyst market seen reaching $0.33M by 2030
The Business Research Company says the global Arcalyst (rilonacept) market will grow from $0.24 million in 2025 to $0.33 million by 2030, driven by more personalized medicine, broader diagnosis of rare inflammatory diseases and wider biologic access. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through 2030.
Why it matters: - Arcalyst (rilonacept) is tied to rare inflammatory diseases where treatment options are limited. - The market’s growth points to rising diagnosis rates, more targeted care and expanding use of biologic therapies. - The forecast suggests more demand for interleukin-1 blocking treatments as rare-disease care becomes more personalized.
What happened: - The Business Research Company published an analysis of the Arcalyst (rilonacept) market on Oct. 29, 2026. - The report projects the market will rise from $0.24 million in 2025 to $0.26 million in 2026. - The report forecasts the market will reach $0.33 million by 2030. - The 2025-2026 growth rate is projected at 7.3%. - The 2026-2030 growth rate is projected at 6.5%. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.
The details: - Arcalyst is a prescription interleukin-1, or IL-1, inhibitor used for specific inflammatory disorders driven by overactive IL-1 protein. - The drug binds to interleukin-1 alpha and beta and blocks their interaction with cell receptors. - That mechanism reduces inflammation and helps relieve symptoms linked to the underlying diseases. - The market’s earlier growth was fueled by recognition of IL-1-driven diseases, limited alternative treatments, positive clinical outcomes, orphan drug approvals and adoption by specialists favoring biologic therapies. - The forecast period is supported by more diagnoses of autoinflammatory syndromes, broader use in new indications, advances in genetic screening, wider access to biologic therapies and higher investment in rare disorders. - Emerging trends include greater use of IL-1 blocking treatments, expanded use in rare autoinflammatory diseases, long-term inflammation control, targeted cytokine inhibition and improved management of chronic inflammatory conditions. - The report says personalized medicine is a major growth driver because it can improve effectiveness, reduce side effects and better match treatment to patient-specific disease patterns. - A February 2024 report from the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The coalition also said 2022 was the eighth straight year that personalized medicines made up at least 25% of all new drug approvals. - The report covers Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific.
Between the lines: - The market remains small in dollar terms, but the forecast implies steady demand for a niche therapy with few direct substitutes. - Growth appears more tied to better diagnosis and precision medicine than to broad population use. - Asia-Pacific’s projected lead suggests future upside may come from expanding healthcare access and diagnostic capacity rather than from mature markets alone. - The report’s emphasis on genetic screening and personalized treatment aligns with the broader shift toward matching rare-disease patients with targeted biologics.
What's next: - Wider diagnosis of autoinflammatory syndromes could keep expanding the addressable patient pool through 2030. - Greater biologic access and more regulatory attention to rare disorders may support additional market growth. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and updated graphics and tables. - More information is available in the full report and a free sample.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia Healthcare Industry Digest
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.